(Press-News.org) CHICAGO – Among patients with new synthetic arteriovenous grafts (a synthetic tube grafted between an artery and vein) for vascular access for hemodialysis, daily ingestion of fish oil did not decrease the proportion of grafts with loss of patency (remaining open) within 12 months, according to a study in the May 2 issue of JAMA. However, fish oil recipients had a longer time without thrombosis (formation of a blood clot), half the thrombosis rate, and a clinically meaningful reduction in frequency of radiological and surgical interventions.
"Optimal hemodialysis requires reliable vascular access. Current options include the arteriovenous fistula [surgical creation of a connection between an artery and vein], synthetic arteriovenous graft, and central venous catheter, which in the United States are used in 55 percent, 21 percent, and 24 percent of prevalent patients receiving hemodialysis, respectively. The arteriovenous graft was the predominant vascular access type in North America during the early 1990s but fell out of favor owing to its high complication rates and associated costs. For example, thrombosis occurs in more than 50 percent of all arteriovenous grafts within 1 year after placement, necessitating a salvage procedure in more than 75 percent," according to background information in the article. To date, multiple interventions have failed to convincingly or consistently reduce thrombosis rates. Because of their antiproliferative, antioxidant, and vasodilatory (dilation) effects, the omega-3 fatty acids found in fish oils have theoretical appeal for preventing development of arteriovenous graft stenosis (narrowing) and thrombosis. A small, single-center prospective study of fish oil prophylaxis showed an improvement in 12-month graft patency.
Charmaine E. Lok, M.D., M.Sc., of the University of Toronto and Toronto General Hospital, and colleagues conducted a randomized controlled trial that compared arteriovenous graft patency and rates of thrombosis and intervention in patients with end-stage renal disease who received fish oil supplementation vs. placebo following creation of an arteriovenous graft. The study was conducted at 15 North American dialysis centers from November 2003 through December 2010, enrolling 201 adults with stage 5 chronic kidney disease (50 percent women, 63 percent white, 53 percent with diabetes), with follow-up for 12 months after graft creation. The participants were randomly allocated to receive fish oil capsules (four 1-gram capsules/day) or matching placebo on day 7 after graft creation. The primary outcome measure for the study was the proportion of participants experiencing graft thrombosis or radiological or surgical intervention during 12 months of follow-up.
The researchers found that there was no significant difference in the proportion of fish oil recipients and placebo recipients with loss of native patency (48 percent [48/99] vs. 62 percent [60/97], respectively. "However, the rate of these events was significantly lower in the fish oil group. The frequency of thrombosis events was reduced by half in the fish oil group, and the frequency of corrective interventions was lower."
The 12-month event-free rate (i.e., no loss of native patency of arteriovenous graft) was 48 percent in the fish oil group, compared with 32 percent in the placebo group. The reasons for arteriovenous graft loss were similar between treatment groups. The 12-month thrombosis-free rate was higher in the fish oil group (64 percent vs. 47 percent).
"Analysis of cardiovascular outcomes demonstrated superior cardiovascular event-free survival in the fish oil group. Compared with baseline, there were clinically significant reductions in systolic blood pressure at 6 months in the fish oil group that were sustained to 12 months," the authors write. "Sixty-four percent (63/99) of patients in the fish oil group compared with 42 percent (41/97) in the placebo group had at least 1 reduction in the dose or frequency of their antihypertensive medications."
"Although the risk of the primary end point was not significantly lower among fish oil recipients, this should be considered in the context of the apparent consistent clinical benefits observed for the secondary outcomes."
The researchers note that the use of arteriovenous grafts has declined over the last 10 years, largely driven by the emphasis on use of fistulas. "Arteriovenous grafts may be suitable for patients receiving hemodialysis whose veins are unsuitable for fistula creation or who have experienced prior problems with fistula nonmaturation. However, compared with functioning fistulas, arteriovenous grafts may require a 3- to 4-fold higher frequency of interventions to maintain equivalent long-term patency. Identification of safe and inexpensive agents that prolong arteriovenous graft patency and reduce the frequency of interventions to salvage graft complications might encourage increased use of grafts."
(JAMA. 2012;307[17]:1809-1816. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Fish Oil and Hemodialysis Graft Patency
In an accompanying editorial, Bradley S. Dixon, M.D., of the University of Iowa, Iowa City, addresses the question of whether clinicians, based on these findings, should consider increasing the use of hemodialysis grafts accompanied by the administration of fish oil and an antiplatelet agent to prolong graft patency.
"Thus far, the available data do not support this approach. Despite the reduction in the rate of graft thrombosis and angioplasty procedures with fish oil, the rate of these events is still lower with arteriovenous fistulas, and fistulas remain the preferred means of hemodialysis access. However, if a patient cannot obtain a fistula and requires a graft, use of fish oil and an antiplatelet agent appears reasonable, pending the results of further studies."
(JAMA. 2012;307[17]:1859-1860. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
###
To contact Charmaine E. Lok, M.D., M.Sc., call Jim Oldfield at 416-946-8423 or email jim.oldfield@utoronto.ca. To contact editorial author Bradley S. Dixon, M.D., call Tom Moore at 319-356-3945 or email thomas-moore@uiowa.edu.
END
The Wake County Economic Development (WCED) (http://www.raleigh-wake.org/home), in partnership with the Greater Raleigh Chamber of Commerce (http://www.raleighchamber.org) and the Chamber's Competitive EDGE4 program, has announced the release of a podcast featuring Joel Kotkin, author of The Next Hundred Million: America in 2050 and keynote speaker for the Greater Raleigh Chamber of Commerce's 2012 Economic Development Forum taking place on Wednesday, May 9 from 10 a.m. to 1:30 p.m. The podcast details the topics of Kotkin's address to be delivered at the event at the Raleigh ...
BOSTON – May 1, 2012 – Scientists at Joslin Diabetes Center have identified a key mechanism of action for the TOR (target of rapamycin) protein kinase, a critical regulator of cell growth which plays a major role in illness and aging. This finding not only illuminates the physiology of aging but could lead to new treatments to increase lifespan and control age-related conditions, such as cancer, type 2 diabetes, and neurodegeneration.
Over the past decade, studies have shown that inhibiting TOR activity, which promotes cell growth by regulating protein synthesis, increases ...
In celebration of Mother's Day, Coconut Bay Beach Resort & Spa, the premier Caribbean all-inclusive resort for romance and family travel, located on St. Lucia's exotic southern coast, is offering an exclusive Mother's Day All-Inclusive Spa getaway package. Give that special lady in your life a present she will cherish forever with savings of up to 50 percent.
This special spa package is perfect for guests looking to rejuvenate skin, restore a sense of well-being and soothe away worries, especially for a multitasking mom in need of pampering. Guests must book their ...
mirabyte Software announces the immediate availability of Discstarter 6, the newest version of its award-winning tool for creating professional looking CD menus and front-ends for CD-ROMs, DVD-ROMs and USB portable media. Discstarter is successfully used for years by many major companies around the world and has become the de facto standard for menus of cover mount CDs published by IT and computer magazines.
Version 6 comes with a completely new and intuitive interface that allows you to configure your front-end or menu with ease. Besides several other refinements the ...
New research reinforces the claim that resveratrol—a compound found in plants and food groups, notably red wine—prolongs lifespan and health-span by boosting the activity of mitochondria, the cell's energy supplier.
"The results were surprisingly clear," said David Sinclair, a professor of genetics at Harvard Medical School and the study's senior author. "Without the mitochondria-boosting gene SIRT1, resveratrol does not work."
The findings are to be published May 1 in the journal Cell Metabolism.
Over the last decade, Sinclair and colleagues including Leonard Guarente ...
When it comes to your wedding, there is nothing more important than savouring the moments that make up the day. However, we can't all stay there forever and live the wedding moments out all day long, so a more feasible and realistic idea is put in place. Wedding photos are the best way to keep hold of moments, and relive the tension, love, nerves, happiness and satisfaction that you feel at your wedding. However, you must have a high quality photographer taking the images, otherwise emotions will be lost, moments will be lost and other important factors that make up your ...
JES, a leading engineering solutions company specializing in foundation repair, basement waterproofing and crawl space moisture control has received a Fantastic 50 award from the Virginia Chamber of Commerce.
The Fantastic 50 recognizes the 50 fastest-growing companies in Virginia. The Fantastic 50 is now in its 17th year and is coordinated by the Virginia Chamber of Commerce. Companies that receive the award must be privately held, have headquarters in Virginia, and show sales between $200,000 and $100 million.
JES was founded in 1993 as basement waterproofing company, ...
DURHAM, N.C.— The largest comprehensive analysis of ClinicalTrials.gov finds that clinical trials are falling short of producing high-quality evidence needed to guide medical decision-making. The analysis, published today in JAMA, found the majority of clinical trials is small, and there are significant differences among methodical approaches, including randomizing, blinding and the use of data monitoring committees.
"Our analysis raises questions about the best methods for generating evidence, as well as the capacity of the clinical trials enterprise to supply sufficient ...
Ragsdale Liggett PLLC attorney Bill Pollock has been invited to join the prestigious Claims and Litigation Management Alliance. Membership is extended to select attorneys based only on nominations from current CLM fellows. The organization is comprised of thousands of insurance companies, corporations, corporate counsel, litigation and risk managers, claims professionals and attorneys who promote the highest standards of litigation management in the defense of clients.
Mr. Pollock is a litigation lawyer and partner at Ragsdale Liggett PLLC in Raleigh, North Carolina. ...
Vision and hearing are so crucial to our daily lives that any impairments usually become obvious to an affected person. Although a number of known genetic mutations can lead to hereditary defects in these senses, little is known about our sense of touch, where defects might be so subtle that they go unnoticed.
In the 1 May issue of the online, open-access journal PLoS Biology, Gary Lewin's laboratory at the Max Delbrück Center for Molecular Medicine (MDC) in Berlin demonstrates that differences in touch sensitivity arise from genetic factors that can also be inherited. ...
